Semmelweis Publications
  • Main page

    • Rubovszky, Gábor Semmelweis University affiliated publications (2021-2026)

    Year:
    Order by:
    Authorship:
    Number of publications: 18
    1.
    Improvement in breast cancer survival across molecular subtypes in Hungary between 2011 and 2020: a nationwide, retrospective study
    Darida, M;Rubovszky, G;Kiss, Z;Szekely, B;Madaras, B;Horváth, Z;Kocsis, J;Sipocz, I;Várnai, M;Balogh, E;Kovács, K;Buga, V;Karamousouli, E;Szabó, TG;Rokszin, G;Fábián, I;Kenessey, I;Wéber, A;Nagy, P;Barcza, Z;Bogos, K;Vokó, Z;Polgár, C
    Q2
    FRONTIERS IN ONCOLOGY
    2025.
    DOI:10.3389/fonc.2025.1465511 (Copy DOI)
    2.
    Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer-Increasing Rates of Breast Conserving Surgery: A Real-World Experience
    Boér, K;Kahán, Z;Landherr, L;Csoszi, T;Máhr, K;Ruzsa, A;Horváth, Z;Budai, B;Rubovszky, G
    Q2
    PATHOLOGY & ONCOLOGY RESEARCH
    2021.
    DOI:10.3389/pore.2021.1609785 (Copy DOI)
    3.
    Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer
    Rubovszky, G;Kocsis, J;Boer, K;Chilingirova, N;Dank, M;Kahan, Z;Kaidarova, D;Kover, E;Krakovska, BV;Mahr, K;Mrinakova, B;Piko, B;Bozovic-Spasojevic, I;Horvath, Z
    Q2
    PATHOLOGY & ONCOLOGY RESEARCH
    2022.
    DOI:10.3389/pore.2022.1610383 (Copy DOI)
    4.
    Fertility preservation in female cancer patients II. Possibilities beside current treatments in different types of cancer
    Dóra, V;Borbála, S;Barbara, H;András, M;Tamás, P;Bence, C;István, K;Gábor, R;Zoltán, N
    Q4
    ORVOSI HETILAP
    2023.
    DOI:10.1556/650.2023.32824 (Copy DOI)
    5.
    Long-Term Dynamic Changes in Cosmetic Outcomes and Patient Satisfaction after Implant-Based Postmastectomy Breast Reconstruction and Contralateral Mastopexy with or without an Ultrapro Mesh Sling Used for the Inner Bra Technique. A Retrospective Correlati
    József, Z;Ujhelyi, M;Ping, O;Domján, S;Fülöp, R;Ivády, G;Ráchel, T;Rubovszky, G;Mészáros, N;Kenessey, I;Mátrai, Z
    Q1
    CANCERS
    2021.
    DOI:10.3390/cancers13010073 (Copy DOI)
    6.
    Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boér, K;Rubovszky, G;Rokszin, G;Abonyi-Tóth, Z;Földesi, C;Dank, M
    Q2
    ONCOTARGETS AND THERAPY
    2021.
    DOI:10.2147/OTT.S309862 (Copy DOI)
    7.
    Glucocorticoid Receptor Isoforms in Breast Cancer Raise Implications for Personalised Supportive Therapies
    Butz, H;Vereczki, V;Budai, B;Rubovszky, G;Gyebrovszki, R;Vida, R;Szocs, E;Gerecs, B;Kohánka, A;Tóth, E;Likó, I;Kacskovics, I;Patócs, A
    D1
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
    2024.
    DOI:10.3390/ijms252111813 (Copy DOI)
    8.
    How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer
    Boér, K;Kaposi, A;Kocsis, J;Horváth, Z;Madaras, B;Sávolt, A;Klément, GB;Rubovszky, G
    Q1
    CANCERS
    2024.
    DOI:10.3390/cancers16172928 (Copy DOI)
    9.
    The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer
    Rubovszky, G;Mészáros, N;Mátrai, Z;Sávolt, A;Ujhelyi, M;Madaras, B;Ganofszky, E;Pintér, T;Budai, B
    Q3
    CANCER INVESTIGATION
    2026.
    DOI:10.1080/07357907.2025.2594128 (Copy DOI)
    10.
    A kolorektális karcinóma immunterápiájának fejlődése
    Németh, Zsuzsanna; Rubovszky, Gábor;
    Q4
    MAGYAR ONKOLÓGIA 0025-0244 2060-0399
    2024.
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,
    11.
    Felfüggeszthető-e az immunellenőrzőpontgátlók adása két év alkalmazást követően? Érvek, gondolatok egy hazai irányelv kialakításához [Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for
    Mangel, László; Balatoni, Tímea; Bogos, Krisztina; Gyulai, Roland; Maráz, Anikó; Rubovszky, Gábor; Ostoros, Gyula; Tamási, Lilla; Polgár, Csaba;
    Q4
    MAGYAR ONKOLÓGIA 0025-0244 2060-0399
    2026.
    Semmelweis University authors: Rubovszky, Gábor, Tamási, Lilla, Polgár, Csaba,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Pulmonology,
    12.
    Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
    Tankova, Tsvetalina; Senkus, Elżbieta; Beloyartseva, Maria; Borštnar, Simona; Catrinoiu, Doina; Frolova, Mona; Hegmane, Alinta; Janež, Andrej; Krnić, Mladen; Lengyel, Zoltan; Marcou, Yiola; Mazilu, Laura; Mrinakova, Bela; Percik, Ruth; Petrakova, Katarina; Rubovszky, Gábor; Tokar, Margarita; Vrdoljak, Eduard;
    Q1
    CANCERS 2072-6694
    2022.
    DOI:10.3390/cancers14071598 (Copy DOI)
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,
    13.
    A metaplasztikus emlődaganat retrospektív elemzése
    Kolossváry, Kinga; Nagy, Réka; Papp, Eszter; Sávolt, Ákos; Tóth, Erika; Rubovszky, Gábor;
    Q4
    MAGYAR ONKOLÓGIA 0025-0244 2060-0399
    2024.
    14.
    The role of everolimus in metastatic breast cancer and possibilities of moving forward-a narrative review.
    Rubovszky, Gabor;
    ANNALS OF TRANSLATIONAL MEDICINE 2305-5839 2305-5847
    2024.
    DOI:10.21037/atm-23-1583 (Copy DOI)
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,
    15.
    Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer
    Agostinetto, E; Pfeiler, G; Hlauschek, D; Mayer, E L; Lambertini, M; de Azambuja, E; Bellet-Ezquerra, M; Meisel, J L; Rubovszky, G; Zdenkowski, N; Novik, Y; Ruiz-Borrego, M; Gelmon, K A; Mamounas, E P; Iwata, H; Lu, D R; Soelkner, L; Fesl, C; Gnant, M; DeMichele, A;
    D1
    ESMO OPEN 2059-7029 2059-7029
    2025.
    DOI:10.1016/j.esmoop.2024.104096 (Copy DOI)
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,
    16.
    Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer
    Cardoso, Fatima; O'Shaughnessy, Joyce; Liu, Zhenzhen; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda L; Cescon, David W; Fasching, Peter A; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gábor; Spring, Laura; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; André, Fabrice; Yasojima, Hiroyuki; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya;
    D1
    NATURE MEDICINE 1078-8956 1546-170X
    2025.
    DOI:10.1038/s41591-024-03415-7 (Copy DOI)
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,
    17.
    Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
    DeMichele, A; Dueck, A C; Hlauschek, D; Martin, M; Burstein, H; Pfeiler, G; Zdenkowski, N; Wolff, A; Bellet-Ezquerra, M; Winer, E; Balic, M; Miller, K; Colleoni, M; Lake, D; Rubovsky, G; Cameron, D; Balko, J; Singer, C F; Nowecki, Z; Iwata, H; Wolmark, N; Parraga, K A; Rugo, H; Steger, G G; Traina, T; Werutsky, G; Czajkowska, D; Metzger, O; El-Abed, S; Theall, K P; Lu, R D; O'Brien, P; Fesl, C; Mayer, E; Gnant, M;
    Q1
    BREAST CANCER RESEARCH 1465-5411 1465-542X
    2025.
    DOI:10.1186/s13058-024-01941-3 (Copy DOI)
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,
    18.
    Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
    Shinn, Eileen; Zahrieh, David; DeMichele, Angela; Zdenkowski, Nick; Lemieux, Julie; Mao, Jun; Bjelic-Radisic, Vesna; Naughton, Michelle J; Pfeiler, Georg; Gelmon, Karen; Balko, Justin M; Egle, Daniel; Zoppoli, Gabriele; Traina, Tiffany; Jimenez, Miguel Martin; Novoa, Silvia Antolin; Haddad, Tufia; Chan, Arlene; Ring, Alistair; Wolff, Antonio; Symmans, William Fraser; Ponce Lorenzo, Jose; Sabanathan, Dhanusha; Burstein, Hal J; Nowecki, Zbigniew Ireneusz; Pristauz-Telsnigg, Gunda; Brufsky, Adam; B...
    Q1
    BREAST CANCER RESEARCH AND TREATMENT 0167-6806 1573-7217
    2025.
    DOI:10.1007/s10549-025-07653-2 (Copy DOI)
    Semmelweis University authors: Rubovszky, Gábor,
    Semmelweis University departments: Semmelweis University, Faculty of Medicine, Department of Radiotherapy, Onkológiai Tanszék,

    Navigation

    Main page

    Publication search

    Department ranking

    Author ranking

    Author search

    Articles recently published in SJR D1 journals

    Top papers of the university

    Top field weighted citation impact publications

    Highly Cited Articles of Semmelweis University

    Semmelweis Publications
    Release: 2026_7
    Department data last refreshed at: 22.06.2026
    Author data last refreshed at: 22.06.2026
    (c) Semmelweis University - Central Library